• NEBANNER

I-MOQ ephantsi yoThengiso olushushu!Ubonelelo lweFactory eMgangathweni oPhezulu weBetrixaban Raw Materials CAS 330942-05-7

I-MOQ ephantsi yoThengiso olushushu!Ubonelelo lweFactory eMgangathweni oPhezulu weBetrixaban Raw Materials CAS 330942-05-7

Inkcazelo emfutshane:


Iinkcukacha zeMveliso

Iithegi zeMveliso

Ukuba linqanaba lokuqonda amaphupha abasebenzi bethu!Ukwakha iqela elonwabileyo, elimanyeneyo nelingaphezulu lobuchwephesha!Ukufikelela kumvuzo ofanayo wabathengi bethu, ababoneleli, uluntu kunye nathi ngokwe-MOQ ephantsi yoThengiso olushushu!IFactory Supply High Quality Betrixaban Raw Materials CAS 330942-05-7, Sinyanisekile kwaye sivulekile.Sijonge phambili ekumiseni nasekusekeni ubudlelwane obuthembekileyo kunye nexesha elide lokuma kwezothando.
Ukuba linqanaba lokuqonda amaphupha abasebenzi bethu!Ukwakha iqela elonwabileyo, elimanyeneyo nelingaphezulu lobuchwephesha!Ukufikelela kumvuzo ofanayo wabathengi bethu, ababoneleli, uluntu kunye nathi ngokwethuChina Pharmaceutical Intermediate kunye 330942-05-7, “Umgangatho olungileyo kunye nexabiso elifanelekileyo” yimigaqo yethu yoshishino.Ukuba unomdla kwizisombululo zethu okanye unemibuzo, khumbula ukuba uzive ukhululekile ukuqhagamshelana nathi.Sinethemba lokuseka ubudlelwane bentsebenziswano nawe kwixesha elizayo elingekude.

Fondaparinux Biological Activity

Chaza I-Fondaparinux sodium yi-antithrombin-dependent factor Xa inhibitor.
EyeleleneyoIindidi indlela yomqondiso >> Metabolic enzymes/proteases >> Factor Xa Iindawo zophando >> Izifo zentliziyo
Ekujoliswe kuko Factor Xa[1]
I-In vitroizifundo I-Fondaparinux i-sodium yi-anticoagulant yokuqala entsha ejolise ngokukhethekileyo kwi-factor Xa.Kwi-Fondaparinux, ixabiso le-IC50 (i-anti-Xa IU/ml) ye-monocytes esebenzayo (ac-M) yi-0.59±0.05, kunye ne-monocyte-derived particles (MMP) yi-0.17±0.03 [2].
Kwi-vivouphando I-Fondaparinux sodium ine-linear, iprofayili ye-pharmacokinetic exhomekeke kwidosi, enika impendulo eqikelelweyo kakhulu.I-Fondaparinux sodium ine-100% ye-bioavailability, inokuqala ngokukhawuleza kwesenzo, inesiqingatha sobomi be-14 kwiiyure ze-16, kwaye inokuqhubeka nokumelana ne-thrombosis kwiiyure ezingama-24.Ichiza alichaphazeli ixesha leprothrombin okanye ixesha le-thromboplastin elisebenzayo, kwaye alichaphazeli ukusebenza kweplatelet okanye ukuhlanganiswa [1].
Iimbekiselo [1].Bauer KA.okqhubekayo.I-Fondaparinux sodium: inhibitor ekhethiweyo ye-factor Xa.Am J Health Syst Pharm.2001 Nov 1;58 Suppl 2:S14-7.[2].UBen-Hadj-Khalifa S, et al.Ukwahlukana kwe-coagulation inhibitory effect ye-fondaparinux, i-enoxaparin kunye ne-heparin engaxutywanga kwiimodeli zeeseli zesizukulwana se-thrombin.Igazi le-Coagul Fibrinolysis.2011 Jul;22(5):369-73.

Iimpawu zeMichiza kunye nezomzimba zeFondaparinux

Ifomula yemolekyuli C31H53N3Na10O49S8
Ubunzima bemolekyuli 1738.16
PSA 900.82000

I-Fondaparinux luhlobo olutsha lwechiza le-antithrombotic elivunywe yi-FDA emva kwe-heparin kunye ne-heparin ephantsi ye-molecular weight kunyango kunye nokuthintela iintlobo ezahlukeneyo ze-arteriovenous thrombosis.

Izibonakaliso: I-Fondaparinux isetyenziselwa izigulane ezenza utyando olukhulu lwamathambo emilenze ephantsi, njengokuphuka kwe-hip, utyando olukhulu lwamadolo okanye ukutshintshwa kwe-hip, ukukhusela i-thromboembolism ye-venous.Isetyenziselwa unyango lwezigulane ezine-angina engazinzanga okanye i-non-ST-segment elevation myocardial infarction ehamba ngokukhawuleza (<120 imizuzu) unyango olungenayo (PCI) ngaphandle kokubonisa.Isetyenziselwa unyango lwezigulane ezine-ST-segment elevation myocardial infarction abasebenzisa i-thrombolysis okanye ekuqaleni abafumani ezinye iindlela zonyango zonyango.

1)Intengiso eqhubekayo ye-Glaxo yemarike iya kuyibeka kwindawo engundoqo yechiza kwindlela elandelayo yezonyango yoMphathiswa wezeMpilo, uhlaziyo lwexabiso leKomishoni yoPhuhliso noHlengahlengiso lweSizwe, kunye ne-inshurensi yezonyango yoBuphathiswa be-Inshurensi yaBantu.

A, Imveliso ayikangeni kwi-inshurensi yezonyango yesizwe.Ngo-2010, uhlengahlengiso lwe-inshorensi yezonyango lusanda kungena kwi-inshurensi yezonyango yasekuhlaleni yamaphondo ali-16.Iintengiso zikwinqanaba lokuqala kwaye ngokuthe ngcembe ziya kuthatha indawo yemarike ye-heparin ephantsi-molekyuli;amaphondo inshorensi yezonyango: Shaanxi, Shanxi, Inner Mongolia, Liaoning, Tibet, Yunnan, Guangdong , Guangxi, Hainan, Jiangsu, Gansu, Fujian, Jiangxi, Henan, Hubei, Beijing.

B, Iimpawu zisakhula.I-GSK okwangoku inezalathisi ezi-3 ekliniki.Ngokomzekelo, iimpawu ze-stents zivunyiwe kuphela.Ezinye iiheparin azikho.Ukusetyenziswa kweklinikhi ye-stents kwandisa ngama-30% ngonyaka.Ngokuvunywa kwezibonakaliso ezintsha, ukuthengisa kuya kwanda.Kwithiyori, zonke izifo eziphathwa yimveliso ye-heparin zinganyangwa yile mveliso.

C, Ixabiso inzuzo, ixabiso elisezantsi le mveliso kwimarike US 132 US dollar ngalinye, e China yi 168 yuan, ixabiso lasekhaya akayi kuhla.Ukuba uthumela ngaphandle, imarike yamazwe ngamazwe inendawo ebanzi;

2) Umda wezobuchwephesha uphezulu, izinto eziluhlaza zenziwe ngamanyathelo angama-75, kwaye i-patent iphelile iminyaka emi-5 (inqaku ngo-2014).Ayivunywanga ngabanye abavelisi.I-synthesis inzima kakhulu.Ayizukwenziwa ngaphantsi kweminyaka eli-10.Umjikelo mde, unzima, kwaye utyalo-mali.phezulu.Bambalwa abakhuphisana basekhaya, kwaye abakhuphisana bamazwe angaphandle baneendleko eziphezulu zempahla ekrwada.Injongo yethu kukunciphisa ngokuqhubekayo iindleko zempahla kunye nokubuyisela i-Glaxo kwimveliso yempahla ekrwada.
I-Hengrui Pharmaceuticals Fondaparinux yamkelwe njengomzekelo wokuqala e-China ngo-2018.
I-Guangdong Runxing Biotechnology Co., Ltd. inemveliso yonyaka ye-210 kg ye-fondaparinux sodium ephakathi kwe-N3 ephakathi, eya kufakwa kwi-2018.

IFondaparinux yaphuhliswa kuqala yiMYLAN IRELAND.Okwangoku, iHengrui Pharmaceuticals, iBorui Pharmaceuticals, iHaisco.

Ukuba linqanaba lokuqonda amaphupha abasebenzi bethu!Ukwakha iqela elonwabileyo, elimanyeneyo nelingaphezulu lobuchwephesha!Ukufikelela kumvuzo ofanayo wabathengi bethu, ababoneleli, uluntu kunye nathi ngokwe-MOQ ephantsi yoThengiso olushushu!IFactory Supply High Quality Betrixaban Raw Materials CAS 330942-05-7, Sinyanisekile kwaye sivulekile.Sijonge phambili ekumiseni nasekusekeni ubudlelwane obuthembekileyo kunye nexesha elide lokuma kwezothando.
I-MOQ ephantsi yeChina Pharmaceutical Intermediate kunye 330942-05-7, “Umgangatho olungileyo kunye nexabiso elifanelekileyo” yimigaqo yethu yoshishino.Ukuba unomdla kwizisombululo zethu okanye unemibuzo, khumbula ukuba uzive ukhululekile ukuqhagamshelana nathi.Sinethemba lokuseka ubudlelwane bentsebenziswano nawe kwixesha elizayo elingekude.


  • Ngaphambili:
  • Okulandelayo:

  • Bhala umyalezo wakho apha kwaye uwuthumele kuthi